• Something wrong with this record ?

Metastasis-directed therapy in oligometastatic prostate cancer

M. Miszczyk, T. Soeterik, G. Marra, A. Matsukawa, SF. Shariat

. 2024 ; 34 (3) : 178-182. [pub] 20240305

Language English Country United States

Document type Review, Meta-Analysis, Journal Article

Persistent link   https://www.medvik.cz/link/bmc24014147

PURPOSE OF REVIEW: To summarize the recent findings on the subject of metastasis-directed therapy (MDT) in the treatment of oligometastatic prostate cancer (omPCa). RECENT FINDINGS: Evidence from two randomized clinical trials (RCTs) and a meta-analysis show favorable toxicity profiles, and the potential to delay androgen-deprivation therapy (ADT) for up to two years in nearly half of patients with metachronous hormone-sensitive omPCa. Another RCT showed promising results of MDT as treatment-escalation method combined with androgen receptor signaling inhibitors (ARSI) in first-line treatment for castration-resistant omPCa.Surveys by radiation oncologists and consensus guidelines advocate for MDT across various omPCa scenarios. Multiple single-arm trials present encouraging results; however, the evidence for the benefit of MDT is still weak requiring further investigation to assess its impact on pivotal endpoints, such as survival and quality of life. SUMMARY: MDT is a promising approach in omPCa, and can be used to defer ADT in newly diagnosed metachronous omPCa patients, or to add to ARSI treatment at first diagnosis of castration-resistance. Ongoing prospective trials are needed to guide its optimal utilization in other settings, and patients should be informed about the evolving landscape of systemic therapies with proven survival benefits alongside MDT options.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24014147
003      
CZ-PrNML
005      
20240905133341.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/MOU.0000000000001169 $2 doi
035    __
$a (PubMed)38426229
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Miszczyk, Marcin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Collegium Medicum - Faculty of Medicine, WSB University, Dąbrowa Górnicza, Poland
245    10
$a Metastasis-directed therapy in oligometastatic prostate cancer / $c M. Miszczyk, T. Soeterik, G. Marra, A. Matsukawa, SF. Shariat
520    9_
$a PURPOSE OF REVIEW: To summarize the recent findings on the subject of metastasis-directed therapy (MDT) in the treatment of oligometastatic prostate cancer (omPCa). RECENT FINDINGS: Evidence from two randomized clinical trials (RCTs) and a meta-analysis show favorable toxicity profiles, and the potential to delay androgen-deprivation therapy (ADT) for up to two years in nearly half of patients with metachronous hormone-sensitive omPCa. Another RCT showed promising results of MDT as treatment-escalation method combined with androgen receptor signaling inhibitors (ARSI) in first-line treatment for castration-resistant omPCa.Surveys by radiation oncologists and consensus guidelines advocate for MDT across various omPCa scenarios. Multiple single-arm trials present encouraging results; however, the evidence for the benefit of MDT is still weak requiring further investigation to assess its impact on pivotal endpoints, such as survival and quality of life. SUMMARY: MDT is a promising approach in omPCa, and can be used to defer ADT in newly diagnosed metachronous omPCa patients, or to add to ARSI treatment at first diagnosis of castration-resistance. Ongoing prospective trials are needed to guide its optimal utilization in other settings, and patients should be informed about the evolving landscape of systemic therapies with proven survival benefits alongside MDT options.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    12
$a nádory prostaty $x patologie $7 D011471
650    _2
$a hormonální protinádorové látky $7 D018931
650    _2
$a antagonisté androgenů $x terapeutické užití $7 D000726
655    _2
$a přehledy $7 D016454
655    _2
$a metaanalýza $7 D017418
655    _2
$a časopisecké články $7 D016428
700    1_
$a Soeterik, Timo $u Department of Radiation Oncology, University Medical Center, Utrecht, The Netherlands
700    1_
$a Marra, Giancarlo $u Department of Urology, San Giovanni Battista Hospital, Città della Salute e della Scienza and University of Turin, Turin, Italy
700    1_
$a Matsukawa, Akihiro $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan $u Department of Urology, Weill Cornell Medical College, New York, New York $u Department of Urology, University of Texas Southwestern, Dallas, Texas, USA $u Research Centre for Evidence Medicine, Urology Department, Tabriz University of Medical Sciences, Tabriz, Iran
773    0_
$w MED00001296 $t Current opinion in urology $x 1473-6586 $g Roč. 34, č. 3 (2024), s. 178-182
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38426229 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133335 $b ABA008
999    __
$a ok $b bmc $g 2143748 $s 1226013
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 34 $c 3 $d 178-182 $e 20240305 $i 1473-6586 $m Current opinion in urology $n Curr Opin Urol $x MED00001296
LZP    __
$a Pubmed-20240725

Find record

Citation metrics

Archiving options